1299 results for "MDMA"
Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program.
Frontiers in psychology – January 01, 2024
Summary
A two-year prevention program targeting youth substance use showed promising results through innovative outreach methods. Field interventions at student parties and social media campaigns effectively reduced interest in emerging substances like ecstasy, cannabidiol, and nitrous oxide. Training sessions for prevention workers and direct engagement with party organizers led to increased awareness and more cautious attitudes toward drug use among young people.
Abstract
The Avenir Santé Association implemented a comprehensive prevention program targeting the consumption of the emerging psychoactive substances ecsta...
[Neurotrophic mechanisms of psychedelic therapy].
Biologie aujourd'hui – January 01, 2019
Summary
Therapeutic effects of psychedelics can last long after the drug is gone, suggesting they trigger lasting brain changes. Studies reveal how compounds like LSD and ketamine (kétamine) impact neurotrophic factors such as BDNF. The central idea is that despite different receptor targets, these psychedelics initiate similar beneficial plastic adaptations in the brain's prefrontal cortex. Positive findings indicate these mechanisms could effectively treat conditions like depression (dépression) and addiction, offering new avenues for mental health care.
Abstract
Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and beh...
Sudden death associated with intravenous injection of toad extract.
Forensic science international – July 01, 2009
Summary
A fatal incident, initially linked to a common street drug, instead revealed a deadly cocktail of toad venom compounds and pharmaceuticals. Forensic analysis successfully identified bufotenine and other potent toxins from toad secretions in the victim's system and the injected material. This discovery underscores the extreme danger of unknown compositions in street drugs, highlighting the critical role of precise toxicological screening.
Abstract
A 24-year-old male died suddenly following the intravenous injection of what was believed to be the ring-derivate amphetamine 'ecstasy' (MDMA). Tox...
Altered states: psilocybin for treatment-resistant depression
The Lancet Psychiatry – May 17, 2016
Summary
A pilot in Psychiatry suggests Psilocybin, a powerful hallucinogen, offers hope for Treatment-resistant depression. In a feasibility study with 12 patients, a regimen combining synthesized psilocybin with psychological support reduced depression scores by around 10 points on the Hamilton Depression Scale after one week. This Medicine, documented in medical literature and Psychedelics and Drug Studies, showed promising safety and preliminary efficacy, with about half the participants still experiencing benefits at three months. This offers hope for the 20% of patients with depression unresponsive to conventional treatments.
Abstract
"Alice remained looking thoughtfully at the mushroom for a minute, trying to make out which were the two sides of it; and as it was perfectly round...
Classic and non‐classic psychedelics for substance use disorder: A review of their historic, past and current research
Addiction Neuroscience – June 22, 2022
Summary
Psychedelics offer a compelling new frontier for substance use disorder, a global public health concern where current psychiatric treatments face challenges. Drug studies present moderate evidence for psilocybin and ketamine in Alcohol Use Disorder, and ketamine for opiate/alcohol withdrawal. THC preparations also aid cannabis/opioid withdrawal symptoms. These substances, often alkaloids from chemical synthesis, influence behavior via neurotransmitter receptors. This fluid area of psychology suggests their significant potential as adjunct therapies, transforming approaches to addiction.
Abstract
Substance use disorder (SUD) is a global public health concern that affects millions of people worldwide. Considering current research, addiction h...
The Prevalence of Dextromethorphan Abuse Among High School Students
PEDIATRICS – November 01, 2006
Summary
A survey of over 4000 high school students revealed 4.9% of 12th-graders reported lifetime abuse of Dextromethorphan, a common cough medicine. This Codeine analog's metabolite, Dextrorphan, produces Phencyclidine-like euphoriant effects via specific pharmacological receptor mechanisms. This prevalence exceeds heroin (4.1%) and rivals methamphetamine (5.5%), underscoring a significant public health issue for psychiatry and respiratory and cough-related research. Among users, 69.2% also reported using LSD, compared to 6.7% of non-users.
Abstract
To the Editor.—Dextromethorphan is the d-isomer of the codeine analog, levorphanol, and the active ingredient in >100 over-the-counter cough and co...
A Systematic Review of Participant Diversity in Psychedelic-Assisted Psychotherapy Trials
OpenAlex – August 25, 2024
Summary
A systematic review of 21 randomized trials (N=1034) reveals a stark lack of diversity in promising psychedelic-assisted therapies. Only 12.2% of participants were Black/African-American and 7.2% Hispanic/Latino, significantly underrepresenting these groups in clinical psychology. These Psychedelics and Drug Studies, involving chemical synthesis of alkaloids influencing neurotransmitter receptors, rarely reported gender identity or sexual orientation (9.5%). This lack of diversity limits generalizability for a psychotherapist, hindering equitable mental health outcomes in psychology.
Abstract
Limited participant diversity in mental health intervention research perpetuates mental health disparities. This issue has become a particularly sa...
Hallucinogen-Persisting Perception Disorder in a 16-Year-Old Adolescent
Psychopharmacology Bulletin – August 12, 2025
Summary
A rare hallucinogen-persisting Perception Disorder (HPPD) was observed in a 16-year-old male, highlighting its infrequent presentation in adolescents. This case, relevant to Clinical psychology and Psychiatry, involved a patient with polysubstance use, including psychedelics like LSD and psilocybin. He experienced persistent auditory and visual hallucinations, a critical aspect of his condition. Within Medicine, aripiprazole (5 mg daily) gradually improved his symptoms, demonstrating a potential treatment for this challenging perceptual disorder. This adds to Drug Studies on managing hallucinations in medical conditions, especially when linked to hallucinogen exposure.
Abstract
Objective Hallucinogen-persisting Perception Disorder (HPPD) is a rare condition characterized by the re-experiencing of one or more perceptual sym...
Psychedelic renaissance: A renewed focus on the clinical utility of hallucinogens
Psychiatry and Clinical Neurosciences Reports – May 16, 2024
Summary
A "psychedelic renaissance" reveals hallucinogens like psilocybin offer rapid, sustained therapeutic effects for mental health. Initial ketamine drug studies showed significant improvement in depressive symptoms in 72 hours for 7 subjects. A recent trial with 59 patients found psilocybin reduced depression scores over 6 weeks, comparable to conventional drugs but with faster onset. This renewed focus in psychology, utilizing biochemical analysis of chemical synthesis and alkaloids, represents a new art of healing.
Abstract
During the 1960s, several studies were conducted to test the therapeutic effects of hallucinogenic drugs, also known as psychedelics, on various di...
The Problem of Pain
Dissent – January 01, 2021
Summary
The Sackler family extracted $10 billion from Purdue Pharma between 2007-2017, paying only $225 million after the company’s 2019 bankruptcy, despite an $8.3 billion penalty. This history reveals how "white market" medicine, driven by business interests, has long blurred lines between healing and harm. Examining diverse historical and scientific studies, one finds that drugs deemed illicit, like psychedelics, can offer therapeutic benefits, challenging the law's distinctions. Psychiatry and criminology often overlook this complex history, perpetuating racial bias in drug policy.
Abstract
The Problem of Pain Sophie Pinkham (bio) White Market Drugs: Big Pharma and the Hidden History of Addiction in America by David Herzberg University...
Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey
PLOS mental health. – December 26, 2025
Summary
Autistic adults show strong interest in psychedelics for mental health support. A computer-assisted web interviewing survey of 261 autistic participants found 77.8% willing to try psychedelics like psilocybin for conditions such as anxiety, often addressed in clinical psychology. Remarkably, 69.7% reported past use, with higher doses correlating with lasting mental health improvements. Descriptive statistics underscore the need for inclusive psychiatry and mental health services, acknowledging autistic individuals' distinct needs compared to neurotypical populations in psychedelics and drug studies.
Abstract
Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress dis...
Festivals following the easing of COVID-19 restrictions: Prevalence of new psychoactive substances and illicit drugs.
Environment international – August 01, 2023
Summary
Wastewater-based epidemiology reveals significant substance abuse during festivals. Analysis of samples from a Spanish city's New Year and summer events identified 11 new psychoactive substances and 7 illicit drugs. High consumption of synthetic cathinones like 3-chloromethcathinone (3-CMC) and dissociatives such as 2F-deschloroketamine (2F-DCK) was evident. The presence of N,N-dimethylpentylone also varied across events. This approach offers a cost-effective way to track dynamic shifts in drug use patterns, complementing traditional public health surveillance.
Abstract
The market for illicit drugs and new psychoactive substances (NPS) has grown significantly and people attending festivals have been identified as b...
The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness
Journal of Psychoactive Drugs – August 19, 2022
Summary
Users of classic serotonergic psychedelics, like ayahuasca and psilocybe mushrooms, reported significantly higher nature relatedness (NR) scores. In a Brazilian survey with over 1,000 participants, current users of ayahuasca/DMT and psilocybe mushrooms showed positive associations with NR, while past LSD users also benefitted. Notably, only current and past use of ayahuasca/DMT remained significant after accounting for sociodemographic factors. Additionally, individuals intending to use psilocybe mushrooms in the future exhibited a notable association with increased NR.
Abstract
This study sought to investigate the effects of different substances on nature relatedness (NR) in the general population. An online cross-sectiona...
Simultaneous Determination of HFBA-Derivatized Amphetamines and Ketamines in Urine by Gas Chromatography-Mass Spectrometry
Journal of Analytical Toxicology – April 01, 2011
Summary
A novel method for analyzing multiple drugs in urine achieved impressive detection limits: 25 ng/mL for amphetamine and 15 ng/mL for methamphetamine, among others. This technique utilized solid-phase extraction and derivatization with heptafluorobutyric anhydride, effectively handling a sample size of 1 mL. In a trial involving 107 urine samples, within-day precision was ≤ 3.1%, and accuracy ranged from 96.0% to 110.7%. This streamlined approach enables efficient confirmation testing for amphetamines and ketamine, enhancing forensic toxicology practices.
Abstract
To facilitate the analysis of targeted drugs under high sample volume testing environment, an extraction, derivatization and gas chromatographic-ma...
Early onset Parkinson's disease in the cycle of 3,4-methylenedioxymethamphetamine and substance use: a case report.
Journal of medical case reports – September 23, 2023
Summary
A compelling case reveals that a 49-year-old man developed early onset Parkinson's disease at 38 after using 3,4-methylenedioxymethamphetamine (MDMA). Despite a family history of Parkinson's, his symptoms emerged significantly earlier. The MDMA use likely triggered this early onset, and he later turned to methamphetamines to manage his symptoms. Treatment complications arose from his HIV diagnosis and antiretroviral therapy, which worsened depressive symptoms. This case underscores the potential link between MDMA use and early Parkinson's development, particularly in genetically vulnerable individuals.
Abstract
Current evidence linking the development of Parkinson's disease after the use of 3,4-methylenedioxymethamphetamine is mixed and limited, with only ...
Associations between psychedelic use and cannabis use disorder in a nationally representative sample.
Drug and alcohol dependence – January 01, 2025
Summary
Recent findings reveal an unexpected connection between psychedelic use and problematic marijuana habits. Analysis of nationwide health surveys shows that people who used psilocybin mushrooms or LSD were roughly twice as likely to develop cannabis-related issues. While DMT, ketamine, and MDMA were also studied, the strongest links were with classic psychedelics. This challenges assumptions about psychedelics' potential role in addiction treatment.
Abstract
Cannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently be...
Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.
Molecular psychiatry – April 01, 2025
Summary
Psychedelics and stimulants reshape brain networks differently, with LSD showing unique effects on the brain's "default mode" - regions active when we're lost in thought. This research tracked brain connectivity changes in 28 healthy volunteers after taking LSD, MDMA, or amphetamine. While all substances altered brain network communication, LSD stood out by increasing connectivity between the brain's command centers while reducing it in visual areas. MDMA and amphetamine showed overlapping but distinct patterns, suggesting each substance uniquely influences how brain regions talk to each other.
Abstract
Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. ...
Is it now time to prepare psychiatry for a psychedelic future?
The British Journal of Psychiatry – May 20, 2024
Summary
Australia has made a landmark decision, rescheduling two psychoactive substances, psilocybin and MDMA, for therapeutic use. Psilocybin, a potent hallucinogen, will treat treatment-resistant depression, while MDMA targets post-traumatic stress disorder. This feature explores the profound implications for psychiatry and psychology, signaling a new era for psychedelics and drug studies. It prompts psychotherapists and health systems to consider the opportunities and challenges arising from these developments, highlighting diverse academic research themes in mental health.
Abstract
Australia has just rescheduled two drugs controlled under the United Nations Psychotropic Drug Conventions, psilocybin and MDMA, as treatments for ...
The Emerging Field of Psychedelic Psychotherapy.
Current psychiatry reports – October 01, 2022
Summary
Breakthrough treatments using psychedelics like MDMA and psilocybin are showing remarkable success rates for mental health conditions. When combined with therapy, these compounds help patients with treatment-resistant depression and PTSD gain profound new perspectives. Psychedelic-assisted therapy offers hope by combining carefully supervised sessions with integration support, leading to lasting improvements in mental wellbeing.
Abstract
Few treatments are available for patients with mood disorders or post-traumatic stress disorder (PTSD) who have already failed multiple interventio...
Qualitative transformations of street-seized ecstasy over a decade: A case study in Rio de Janeiro (Brazil).
Journal of forensic sciences – July 01, 2024
Summary
Brazilian ecstasy tablets underwent dramatic changes over a decade, with chemical profiling revealing a complex mix of substances. Analysis of seized drugs showed MDMA being increasingly cut with substances like caffeine and clobenzorex. Major events in Rio affected drug composition patterns, while highway-linked samples suggested targeted distribution to truck drivers.
Abstract
The illegal drug market is constantly evolving, with new drugs being created and existing ones being modified. Adulterants are often added to the m...
Australia's psychedelic experiment: reflections from a psychiatrist clinical researcher.
Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists – June 26, 2025
Summary
Australia has taken a bold step, making psychedelics like MDMA and psilocybin available for therapy. A psychiatrist involved in clinical trials reflects on key areas to ensure patient safety and optimal results. This includes understanding efficacy, ideal psychotherapy models, and support for these treatments. The availability of psychedelic-assisted therapy emphasizes the importance of careful investigation, leading to refined care and improved patient outcomes.
Abstract
BackgroundDespite a limited evidence base to inform clinicians, Australia has adopted a national approach in rescheduling psilocybin and MDMA as cl...
Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.
Health policy (Amsterdam, Netherlands) – July 08, 2025
Summary
Australia's TGA has pioneered psychedelic medicine, approving MDMA for PTSD and Psilocybin for depression. Globally, therapeutic uses for substances like LSD, DMT, and Ketamine (an NMDA antagonist) are explored. Health Canada and the Netherlands support controlled trials; New Zealand explores. India's NDPS act maintains strict bans. These diverse regulatory paths are shaping promising new mental health treatments.
Abstract
Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions...
Tags
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
The International journal on drug policy – January 01, 2022
Summary
While psychedelic-assisted therapy with compounds like MDMA, psilocybin, LSD (lysergic acid), ibogaine, ayahuasca, and dimethyltryptamine shows promising results for mental health, a review of National Institutes of Health (NIH) research funding from 2006-2020 found zero direct grants for clinical trials. Researchers examined NIH databases for support of these hallucinogens and other psychedelics. Despite a global "psychedelic renaissance" and other nations' governments funding such work, the NIH has not directly supported clinical trials for these innovative therapies.
Abstract
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistent...
The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity
Biological Psychiatry – January 10, 2014
Summary
MDMA significantly influences brain activity, particularly in the medial temporal lobes (MTLs), which are crucial for memory and emotion. In a study utilizing resting state fMRI with a sample size of 30 participants, MDMA enhanced cerebral blood flow, leading to increased connectivity in regions like the amygdala and hippocampus. This modulation may explain the euphoriant and hallucinogenic effects associated with the drug. Understanding these mechanisms can advance knowledge in psychology and neuroscience, particularly regarding neurotransmitter receptor influence on behavior.
Abstract
The MTLs appear to be specifically implicated in the mechanism of action of MDMA, but further work is required to elucidate how the drug's characte...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
Attitudes Toward Psychedelic Treatments by Individuals With Histories of Substance Use or Psychiatric Disorders: A Survey Study.
Journal of addiction medicine – May 28, 2025
Summary
Patient perceptions of psychedelic-assisted treatment are shifting dramatically, with 72% of individuals with substance use disorder or psychiatric disorders believing in their therapeutic potential. A comprehensive survey revealed that among 192 participants, two-thirds had prior psychedelic experience. Those with firsthand experience using substances like psilocybin or MDMA showed significantly higher openness to trying psychedelic therapy. While some participants expressed concerns about risks, nearly 70% would consider this treatment for their own conditions.
Abstract
Psychedelics may be promising treatments for substance use disorders (SUD). This study aims to understand how individuals with alcohol use disorder...
From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice
Pharmacology Research & Perspectives – April 01, 2025
Summary
The effectiveness of psychedelic therapies, like MDMA for PTSD, hinges on how they're regulated. Current medicine reviews face challenges assessing drug-assisted psychotherapy, especially when demanding two successful phase 3 randomized controlled trials. Issues with blinding and internal validity arise. The critical distinction for external validity is whether these are standalone drugs or integrated with a psychotherapist. For standalone drugs, trustworthiness is low; for drug-assisted psychology therapies, trustworthiness is high. Avoiding the extrapolation fallacy is key for psychiatry and clinical psychology to prevent rejecting effective treatments.
Abstract
ABSTRACT The recent review of a new drug application for MDMA‐assisted therapy for posttraumatic stress disorder by the United States' Food and Dru...
Is there a place for psychedelics in sports practice?
Acta Neuropsychiatrica – January 01, 2025
Summary
Psilocybin and other hallucinogens are emerging as powerful psychological interventions for Anxiety and other psychiatric conditions, showing potential benefits in Medicine. While Athletes could benefit from such Psychology-based approaches, specific data on how substances like Psilocybin, Lysergic acid diethylamide (LSD), or MDMA affect their physical performance is largely absent. Preclinical Psychedelics and Drug Studies hint at anti-inflammatory properties, unlike nonsteroidal drugs. Understanding Neurotransmitter Receptor Influence on Behavior in performance, crucial for Forensic Toxicology and Drug Analysis, requires further investigation.
Abstract
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use d...
Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Psychedelic-assisted therapy shows promising results in treating moral injury - psychological trauma from events that violate one's core values. Studies examining MDMA, psilocybin, and LSD combined with psychotherapy reveal significant improvements in self-compassion, forgiveness, and PTSD symptoms. The treatments particularly help those struggling with trauma-related moral conflicts and self-acceptance.
Abstract
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery ...
Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders
ACS Pharmacology & Translational Science – February 10, 2025
Summary
Autism Spectrum Disorders affect millions globally, presenting significant challenges in social interaction. A compelling perspective in cognitive psychology explores how psychedelics like LSD, psilocybin, and MDMA may positively influence pro-social behaviors. This viewpoint examines their neurotransmitter receptor influence on behavior, suggesting novel drug studies. Understanding these mechanisms, alongside insights from nicotinic acetylcholine receptors, could offer new psychological approaches for individuals with ASD.
Abstract
Autism Spectrum Disorders (ASD) are complex neurodevelopmental conditions characterized by deficits in social interaction, communication, and repet...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Journal of Psychoactive Drugs – January 29, 2025
Summary
A survey of 1,486 US adults (67.1% male) provides crucial insights into the evolving landscape of psychedelics and drug studies. Predominantly, people use MDMA and LSD recreationally, often orally. While acute effects like hallucinations and positive mood are common, residual headaches also occur. This psychology research offers a valuable scale for understanding public experiences with these chemical synthesis alkaloids. Deciphering this complex data helps us navigate the rabbit hole of diverse academic research themes surrounding psychedelics.
Abstract
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better und...
Uncovering Psychedelics: From Neural Circuits to Therapeutic Applications
Pharmaceuticals – January 19, 2025
Summary
Psychedelics, including psilocybin and MDMA, are demonstrating significant therapeutic efficacy for challenging psychiatric conditions, profoundly impacting Psychology. These powerful hallucinogens alter Consciousness by modulating brain connectivity, particularly the Default Mode Network, a key finding in Neuroscience. Clinical trials show these Psychedelics and Drug Studies enhance neural plasticity, making the brain more adaptable. Their influence on neurotransmitter receptors underpins these effects, offering new insights into human Cognition and potential treatments for rigid thought patterns.
Abstract
Psychedelics, historically celebrated for their cultural and spiritual significance, have emerged as potential breakthrough therapeutic agents due ...
Informed Consent in Psychedelic-Assisted Therapy.
Current topics in behavioral neurosciences – December 31, 2024
Summary
As psychedelic therapy gains medical recognition, proper informed consent becomes crucial for patient safety. MDMA and psilocybin treatments show promising benefits for mental health, but require careful consideration of risks. Healthcare providers must clearly communicate potential outcomes, duration of effects, and integration support. This ensures patients make educated decisions about their treatment journey.
Abstract
Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymetham...
Exploring the substitution of cannabis for alcohol and other drugs among a large convenience sample of people who use cannabis.
Harm reduction journal – November 05, 2024
Summary
Cannabis shows promise as a harm reduction tool, with 60% of users reporting reduced alcohol consumption when using cannabis. In a large New Zealand study, participants also reported decreased use of methamphetamine and other harmful substances. While cannabis co-use with MDMA and LSD showed minimal impact, tobacco use increased for some. Young adults were most likely to substitute cannabis for alcohol, with cultural and lifestyle factors playing key roles in usage patterns.
Abstract
The substitution of cannabis for alcohol and other drugs has been conceptualised in a harm reduction framework as where cannabis is used to reduce ...
Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy
Clinical Pharmacology & Therapeutics – September 30, 2024
Summary
Genetic variations significantly influence how individuals respond to **psychedelics**, a critical insight for future **medicine**. **Pharmacogenomics** explores how our genes affect the **pharmacology**, specifically **pharmacokinetics** and **pharmacodynamics**, of **hallucinogens** like **Psilocybin** and **MDMA**. For instance, genetic variants in enzymes such as **CYP2D6** impact acute effects, suggesting personalized **dosing** may be appropriate. This field, crucial for **drug studies**, aims to improve the safety and therapeutic profile of these compounds, potentially leveraging **biochemical analysis** and understanding **chemical synthesis** for better patient outcomes.
Abstract
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for whic...
Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents
Neuroscience & Biobehavioral Reviews – September 20, 2024
Summary
Psychedelics show significant potential for treating anxiety and maladaptive memories from aversive stimuli. A review of nearly 400 studies since 1957 reveals various psychedelics, like psilocybin and MDMA, reduce the expression of learned fear and impair memory reconsolidation in rodents. This Neuroscience and Psychology research highlights how Psychedelics and Drug Studies modulate neurotransmitter receptor influence on behavior. Understanding these effects, vital for Developmental psychology regarding memory aging, promises new therapeutic strategies for stress-related conditions.
Abstract
Threatening events and stressful experiences can lead to maladaptive memories and related behaviors. Existing treatments often fail to address thes...
Exploring the regulatory framework of psychedelics in the US & Europe.
Asian journal of psychiatry – December 01, 2024
Summary
While most psychedelics remain heavily restricted, regulatory shifts are emerging as research reveals their therapeutic promise. The US and EU are developing frameworks to evaluate substances like psilocybin, LSD, and MDMA for mental health treatment. Ketamine clinics already operate legally in many areas, while magic mushrooms face varying local policies. New laws aim to balance patient access with safety controls.
Abstract
Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic...
Tags
Psychedelics as a tool for a more connected and sustainable world? Considering the importance of rituals, boundaries, and commitment.
International Journal of Drug Policy – September 05, 2024
Summary
Despite a decade of interest in psychedelics like LSD and MDMA for mental health, their social and environmental impacts often go unaddressed. To foster beneficial outcomes, three crucial insights emerge: the importance of setting and rituals, establishing boundaries, and recognizing the long-term commitment required. Commercialization threatens to strip away historical contextual factors, which Psychology and Sociology show are vital. A cautious approach, far from a quick fix, is essential for harnessing these substances' transformative potential for society and the environment.
Abstract
Despite the surge of interest in psychedelic research in the past decade, largely due to the promise of psychedelics for improving mental health ou...
Therapeutic Potential of Psychedelic Drugs: Navigating High Hopes, Strong Claims, Weak Evidence, and Big Money
Annual Review of Psychology – August 02, 2024
Summary
Psychedelics show therapeutic potential in emerging drug studies. Psilocybin, a hallucinogen, shows promise for depression, end-of-life dysphoria, and alcohol use disorder. MDMA (Ecstasy) is being explored for PTSD. While these chemical synthesis compounds, like ketamine, carry adverse effect risks such as addiction and cystitis, their benefits for treatment-resistant depression are emerging. Understanding their precise mechanisms is crucial for psychology and psychiatry. Rigorous evaluation can guide safe clinical use, minimizing harm and informing psychotherapist practices.
Abstract
Therapeutic claims about many psychedelic drugs have not been evaluated in any studies of even modest rigor. The science of psychedelic drugs is st...
Current Perspectives on the Clinical Research and Medicalization of Psychedelic Drugs for Addiction Treatments: Safety, Efficacy, Limitations and Challenges.
CNS drugs – October 01, 2024
Summary
Psychedelic medicines show promising results in treating addiction, with success rates significantly higher than traditional methods. Recent clinical trials reveal that substances like psilocybin and MDMA, when administered in controlled medical settings, can help break destructive patterns of substance use. These treatments work by promoting neuroplasticity and addressing underlying trauma, offering new hope for those struggling with addiction where conventional treatments have failed.
Abstract
Mental health disorders and substance use disorders (SUDs) in particular, contribute greatly to the global burden of disease. Psychedelics, includi...
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
The International journal on drug policy – August 01, 2024
Summary
A groundbreaking international survey reveals that personal growth, not recreation, is the primary motivation for psychedelic use across global regions. This comparative analysis of 6,379 adults from 85 countries found that psilocybin, LSD, and MDMA are the most commonly used substances. Usage patterns vary by region, with North Americans more likely to microdose and seek therapeutic benefits. Most users prefer legal, quality-controlled sources and practice infrequent, intentional use.
Abstract
Despite advancements in policies governing psychedelic substances globally, our understanding of real-world psychedelic use and its variations acro...
In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
Psychopharmacology – June 01, 2024
Summary
Breakthrough treatments combining psychedelics with assisted therapy are showing remarkable promise in mental health care. This analysis of clinical trials reveals that MDMA and other psychedelic compounds, when paired with professional therapy, can effectively treat various psychiatric conditions. However, creating truly blind studies proves challenging, as participants often recognize when they've received a placebo versus an active substance.
Abstract
Recent years have seen a resurgence in randomized, placebo controlled trials (RCTs) utilizing non-classical psychedelics (e.g. 3,4-methyl enedioxy ...
Valuing the Acute Subjective Experience
Perspectives in biology and medicine – January 01, 2024
Summary
A compelling idea emerges in **psychology**: experiences with **hallucinogens** like **psilocybin** and **MDMA** may hold intrinsic **value** (mathematics) beyond measurable therapeutic outcomes. While **medicine** and **mental health** research often focus on symptom alleviation or well-being increases, this essay challenges that narrow view. It explores how the acute subjective experience, impacting **consciousness**, could be profoundly valuable in itself. Drawing on aesthetics and **epistemology**, it offers **psychotherapists** and **social psychology** a richer understanding of these **psychedelics**, moving beyond solely outcome-based evaluations in **drug studies**.
Abstract
ABSTRACT: Psychedelics, including psilocybin, and other consciousness-altering compounds such as 3,4-methylenedioxymethamphetamine (MDMA), currentl...
Intensity of Psychoactive Substance Use Affects the Occurrence of Prodromal Symptoms of Psychosis.
Journal of clinical medicine – January 28, 2024
Summary
Heavy drug use may predict early warning signs of psychosis, according to data from 703 substance users. Higher scores on drug addiction screenings (DUDIT) strongly correlated with increased prodromal symptoms - early indicators that can precede serious mental health conditions. Cannabis, MDMA, and amphetamine users who started earlier in life showed greater risk of developing these concerning symptoms. The findings highlight the link between substance intensity and psychological vulnerability.
Abstract
Psychosis is defined as a series of symptoms that impair the mind and lead to a kind of loss of reference to reality. Development of psychosis is u...
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.
Current neuropharmacology – January 01, 2024
Summary
Groundbreaking research reveals promising results in treating PTSD with psychedelics. Clinical trials show substances like psilocybin, MDMA, and ketamine can significantly reduce trauma symptoms when combined with therapy. LSD and ayahuasca also demonstrate potential in healing psychological wounds, offering hope to millions affected by PTSD who haven't responded to conventional treatments.
Abstract
Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 mil...
Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.
Drug discovery today – December 01, 2023
Summary
Psychedelics like psilocybin and MDMA are showing remarkable promise in treating severe psychiatric disorders, with success rates exceeding 60% in some clinical trials. These substances, when combined with therapy, offer new hope for treating depression, anxiety, and posttraumatic stress disorder where traditional treatments have failed. Early results demonstrate lasting positive changes in brain connectivity and emotional processing.
Abstract
Psychiatric disorders represent the largest cause of disability worldwide. Global interests in psychedelic substances as potentially therapeutic ag...
Tryptamines and Mental Health: Activating the 5-HT Receptor for Therapeutic Potential
ACS Medicinal Chemistry Letters – September 15, 2023
Summary
Breakthroughs in Medicine reveal tryptamines, a class of alkaloids, are revolutionizing mental health treatments. Psilocybin and MDMA, known psychedelics, received FDA "breakthrough therapy" status for depression and PTSD. These compounds, acting on the 5-HT receptor, a key neurotransmitter receptor, significantly improve patient outcomes. Ongoing Pharmacology and Drug Studies leverage Chemistry and chemical synthesis to explore these potent agents. Data science, analyzing patient-reported outcomes, underscores their profound influence on behavior. While specific data on sample sizes or percentages were not provided, their therapeutic promise is clear.
Abstract
Tryptamines, a class of 3-aminoethyl-indoles that activate the serotonin receptor, show potential for novel mental health treatments. The FDA has g...
Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City
Journal of Psychoactive Drugs – August 21, 2023
Summary
Summer significantly increases psychedelic use among nightclub and festival attendees. An epidemiological survey of 3,935 adults across 15 seasons revealed summer was associated with a 2.72 odds ratio for Lysergic acid diethylamide use and 1.65 odds ratio for Psilocybin. These Psychedelics and Drug Studies findings highlight seasonal hallucinogen consumption patterns. Understanding this demography is crucial for targeted harm reduction efforts, particularly concerning MDMA (Ecstasy) and public health medicine.
Abstract
Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival atten...
Strong increase in the number of intoxications involving psychoactive drugs among adolescents reported to the Dutch Poisons Information Center from 2014-2023.
The International journal on drug policy – August 01, 2025
Summary
Dutch poison control data reveals a troubling surge in adolescent intoxications from psychoactive drugs, with cases nearly tripling over the past decade. Cannabis edibles, MDMA, and new psychoactive substances led this increase. Notable shifts include a 208% rise in cannabis-related incidents and emergence of novel synthetic drugs. The findings highlight evolving patterns in youth substance use and underscore growing public health concerns.
Abstract
The use of psychoactive drugs has been increasing worldwide, with adolescents and young adults accounting for a large share of people who use drugs...